Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells

(2017) David H. Raulet et al.   IMMUNOLOGICAL REVIEWS

CD56bright NK cells exhibit potent antitumor responses following IL-15 priming

(2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger   JOURNAL OF CLINICAL INVESTIGATION

LFA-1 Activation in NK Cells and Their Subsets: Influence of Receptors, Maturation, and Cytokine Stimulation

(2017) Doris Urlaub et al.   JOURNAL OF IMMUNOLOGY

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)

(2017) Caroline Jochems et al.   Oncotarget

Cd226−/− natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo

(2017) Ji Sung Kim et al.   OncoImmunology

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

(2017) Sheila López-Cobo et al.   OncoImmunology

Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis

(2017) Simin Kiany et al.   OncoImmunology

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

(2017) Renee N. Donahue et al.   Journal for ImmunoTherapy of Cancer

The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3

(2017) Lulu Ni et al.   Scientific Reports

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma

(2017) Cathrin Ritter et al.   Scientific Reports

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Targeting natural killer cells in cancer immunotherapy

(2016) Camille Guillerey et al.   NATURE IMMUNOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

(2016) Rika Fujii et al.   Oncotarget

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

(2016) Sofia R. Gameiro et al.   Oncotarget

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response inKRASwild-type metastatic colorectal cancer patients

(2016) Cristiana Lo Nigro   World Journal of Gastrointestinal Oncology

Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis

(2015) J Wild et al.   LEUKEMIA

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance

(2015) A M Martin et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Epigenetic therapy for solid tumors: from bench science to clinical trials

(2015) Yen-Yi Juo et al.   Epigenomics

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer

(2015) Christopher R. Heery et al.   JAMA Oncology

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition

(2013) Eric O. Long et al.   Annual Review of Immunology

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor

(2013) Marian Iwamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

(2013) Madeleine SQ Kortenhorst et al.   Epigenetics

The future of epigenetic therapy in solid tumours—lessons from the past

(2013) Nilofer Azad et al.   Nature Reviews Clinical Oncology

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells

(2013) Shiguo Zhu et al.   PHARMACEUTICAL RESEARCH

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection

(2013) Joachim Koch et al.   TRENDS IN IMMUNOLOGY

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects

(2012) Alison C. West et al.   OncoImmunology

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

(2011) R Pili et al.   BRITISH JOURNAL OF CANCER

Entinostat for treatment of solid tumors and hematologic malignancies

(2011) Jeffrey Knipstein et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer

(2010) Teemu T. Junttila et al.   CANCER RESEARCH

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY

Histone deacetylases and the immunological network: implications in cancer and inflammation

(2009) A Villagra et al.   ONCOGENE

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

(2008) Mareike Schmudde et al.   CANCER LETTERS

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY